MX2021013844A - Anticuerpos biespecificos activables que comprenden un enlazador entre los dos dominios de union, que es una region bisagra de inmunoglobulina humana, o una variante de esta, y usos de estos. - Google Patents
Anticuerpos biespecificos activables que comprenden un enlazador entre los dos dominios de union, que es una region bisagra de inmunoglobulina humana, o una variante de esta, y usos de estos.Info
- Publication number
- MX2021013844A MX2021013844A MX2021013844A MX2021013844A MX2021013844A MX 2021013844 A MX2021013844 A MX 2021013844A MX 2021013844 A MX2021013844 A MX 2021013844A MX 2021013844 A MX2021013844 A MX 2021013844A MX 2021013844 A MX2021013844 A MX 2021013844A
- Authority
- MX
- Mexico
- Prior art keywords
- activable
- linker
- variant
- human immunoglobulin
- hinge region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1906685.1A GB201906685D0 (en) | 2019-05-13 | 2019-05-13 | Activatable protein constructs and uses thereof |
| GBGB1910254.0A GB201910254D0 (en) | 2019-05-13 | 2019-07-17 | Activatable protein constructs and uses thereof |
| GBGB1917678.3A GB201917678D0 (en) | 2019-05-13 | 2019-12-04 | Activatable protein constructs and uses thereof |
| GBGB2001196.1A GB202001196D0 (en) | 2019-05-13 | 2020-01-28 | Activatable protein constructs and uses thereof |
| PCT/EP2020/063362 WO2020229553A1 (en) | 2019-05-13 | 2020-05-13 | Activatable bispecific antibodies comprising a linker between the two binding domains which is a human immunoglobulin hinge region, or a variant thereof, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013844A true MX2021013844A (es) | 2022-03-17 |
Family
ID=67384589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013844A MX2021013844A (es) | 2019-05-13 | 2020-05-13 | Anticuerpos biespecificos activables que comprenden un enlazador entre los dos dominios de union, que es una region bisagra de inmunoglobulina humana, o una variante de esta, y usos de estos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230192899A1 (enExample) |
| EP (1) | EP3969116A1 (enExample) |
| JP (2) | JP7617027B2 (enExample) |
| KR (1) | KR20220008841A (enExample) |
| CN (2) | CN113840634B (enExample) |
| AU (1) | AU2020276891A1 (enExample) |
| BR (1) | BR112021022661A2 (enExample) |
| CA (1) | CA3138827A1 (enExample) |
| GB (4) | GB201906685D0 (enExample) |
| IL (1) | IL287890A (enExample) |
| MX (1) | MX2021013844A (enExample) |
| SG (1) | SG11202112114YA (enExample) |
| WO (1) | WO2020229553A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3428194T (lt) | 2017-07-14 | 2021-12-10 | Immatics Biotechnologies Gmbh | Pagerinta dvejopo savitumo polipeptido molekulė |
| GB201906685D0 (en) * | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| JP2022548310A (ja) * | 2019-09-23 | 2022-11-17 | シートムエックス セラピューティクス，インコーポレイテッド | 抗ｃｄ４７抗体、活性化可能抗ｃｄ４７抗体、およびその使用方法 |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| US20240002509A1 (en) * | 2020-11-06 | 2024-01-04 | Novartis Ag | ANTIBODY Fc VARIANTS |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| CA3251615A1 (en) * | 2022-01-31 | 2023-08-03 | Centessa Pharmaceuticals (Uk) Limited | Activable Bispecific Anti-CD47 and Anti-PD-L1 Proteins and Their Uses |
| IL315768A (en) * | 2022-03-30 | 2024-11-01 | Centessa Pharmaceuticals Uk Ltd | Bispecific anti-CD3 and anti-PD-L1 activatable proteins and their uses |
| WO2023192973A1 (en) * | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| AU2023271317A1 (en) | 2022-05-16 | 2024-11-07 | Byondis B.V. | Novel masked antibodies |
| GB202302074D0 (en) * | 2023-02-14 | 2023-03-29 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2024218512A1 (en) * | 2023-04-19 | 2024-10-24 | Centessa Pharmaceuticals (Uk) Limited | Activatable bispecific anti-cd89 and anti-pd-l1 proteins and uses thereof |
| EP4698562A1 (en) * | 2023-04-19 | 2026-02-25 | Centessa Pharmaceuticals (UK) Limited | Activatable bispecific anti-cd28 and anti pd-l1 proteins and uses thereof |
| WO2024241208A1 (ko) * | 2023-05-19 | 2024-11-28 | 서울대학교산학협력단 | Cd3 유전자 편집된 cd3 표적 스위처블 car-t 세포 |
| CN121866269A (zh) * | 2023-09-14 | 2026-04-14 | Abl生物公司 | 通过施用抗pd-l1/抗4-1bb双特异性抗体治疗癌症的方法 |
| WO2026038050A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2026038048A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2026038047A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2352763T4 (da) * | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
| ES2623912T3 (es) | 2010-12-23 | 2017-07-12 | Janssen Biotech, Inc. | Mutantes FC de anticuerpo activo resistente a proteasa |
| MX2017003847A (es) * | 2014-09-25 | 2017-12-15 | Amgen Inc | Proteinas biespecificas activables por proteasas. |
| JP7065782B2 (ja) * | 2016-03-18 | 2022-05-12 | フレッド ハッチンソン キャンサー リサーチ センター | Ｃｄ２０免疫療法のための組成物および方法 |
| WO2017162587A1 (en) * | 2016-03-22 | 2017-09-28 | F. Hoffmann-La Roche Ag | Protease-activated t cell bispecific molecules |
| SG11201909160WA (en) * | 2017-04-11 | 2019-10-30 | Inhibrx Inc | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| CN111212852A (zh) | 2017-08-18 | 2020-05-29 | 超人肆有限公司 | 结合剂 |
| GB201803892D0 (en) | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
| GB201906685D0 (en) * | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
-
2019
- 2019-05-13 GB GBGB1906685.1A patent/GB201906685D0/en not_active Ceased
- 2019-07-17 GB GBGB1910254.0A patent/GB201910254D0/en not_active Ceased
- 2019-12-04 GB GBGB1917678.3A patent/GB201917678D0/en not_active Ceased
-
2020
- 2020-01-28 GB GBGB2001196.1A patent/GB202001196D0/en not_active Ceased
- 2020-05-13 MX MX2021013844A patent/MX2021013844A/es unknown
- 2020-05-13 SG SG11202112114YA patent/SG11202112114YA/en unknown
- 2020-05-13 CA CA3138827A patent/CA3138827A1/en active Pending
- 2020-05-13 JP JP2021565875A patent/JP7617027B2/ja active Active
- 2020-05-13 WO PCT/EP2020/063362 patent/WO2020229553A1/en not_active Ceased
- 2020-05-13 CN CN202080034818.9A patent/CN113840634B/zh active Active
- 2020-05-13 BR BR112021022661A patent/BR112021022661A2/pt unknown
- 2020-05-13 KR KR1020217038644A patent/KR20220008841A/ko active Pending
- 2020-05-13 AU AU2020276891A patent/AU2020276891A1/en active Pending
- 2020-05-13 CN CN202510701821.6A patent/CN120554533A/zh active Pending
- 2020-05-13 EP EP20726749.3A patent/EP3969116A1/en active Pending
- 2020-05-13 US US17/610,899 patent/US20230192899A1/en active Pending
-
2021
- 2021-11-07 IL IL287890A patent/IL287890A/en unknown
-
2025
- 2025-01-06 JP JP2025001728A patent/JP2025039660A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020229553A1 (en) | 2020-11-19 |
| CN113840634A (zh) | 2021-12-24 |
| EP3969116A1 (en) | 2022-03-23 |
| JP7617027B2 (ja) | 2025-01-17 |
| GB201906685D0 (en) | 2019-06-26 |
| GB201917678D0 (en) | 2020-01-15 |
| CN113840634B (zh) | 2025-07-08 |
| BR112021022661A2 (pt) | 2022-03-29 |
| GB202001196D0 (en) | 2020-03-11 |
| US20230192899A1 (en) | 2023-06-22 |
| GB201910254D0 (en) | 2019-08-28 |
| CA3138827A1 (en) | 2020-11-19 |
| AU2020276891A1 (en) | 2021-12-23 |
| IL287890A (en) | 2022-01-01 |
| KR20220008841A (ko) | 2022-01-21 |
| JP2022532534A (ja) | 2022-07-15 |
| CN120554533A (zh) | 2025-08-29 |
| JP2025039660A (ja) | 2025-03-21 |
| SG11202112114YA (en) | 2021-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013844A (es) | Anticuerpos biespecificos activables que comprenden un enlazador entre los dos dominios de union, que es una region bisagra de inmunoglobulina humana, o una variante de esta, y usos de estos. | |
| BR112022014667A2 (pt) | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos | |
| BR112022000371A2 (pt) | Anticorpos claudin18 e métodos de tratamento contra câncer | |
| WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
| PE20200152A1 (es) | Receptores de union a antigeno mejorados | |
| BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
| BR112022013236A2 (pt) | Anticorpos anti-cd73 e usos dos mesmos | |
| CL2022000300A1 (es) | Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252) | |
| BR112022027096A2 (pt) | Composições e métodos relacionados a agentes terapêuticos ativáveis | |
| ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| BR112018070676A2 (pt) | construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos | |
| BR112022012327A2 (pt) | Anticorpos ou fragmentos dos mesmos, ácido nucleico, vetor e célula hospedeira | |
| EA201990781A9 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
| JOP20200313A1 (ar) | أجسام مضادة dll3-cd3 ثنائية الخاصية | |
| BR122020002402B8 (pt) | Proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, célula hospedeira recombinante, métodos de confecção da referida proteína de ligação e uso da mesma | |
| AR106570A1 (es) | Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos | |
| MX2022001049A (es) | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos. | |
| AR069681A1 (es) | Moleculas de union al receptor ox40 humano | |
| EP4696785A3 (en) | Anti-pd-1 antibodies | |
| MX2021011330A (es) | Anticuerpos de claudina-6 y conjugados de fármacos. | |
| AR066198A1 (es) | Anticuerpos anti ige apoptoticos | |
| BR112013004266A8 (pt) | anticorpos anti-ox40 e métodos de uso dos mesmos. | |
| BR112012013915A8 (pt) | anticorpos anti-c4. 4a e usos dos mesmos | |
| CL2022000096A1 (es) | Anticuerpos anti-tigit y aplicación de los mismos | |
| MX2024014591A (es) | Anticuerpo anti-bdca2 y uso del mismo |